Journal of Integrative Natural Science (통합자연과학논문집)

The Basic Science Institute Chosun University (조선대학교 기초과학연구원)
권호 표지
DOI QR코드

DOI QR Code

Molecular Docking Study of Novel Anti-Hepatitis B Virus Agents Isolated from Talaromyces Species

  • Babu, Sathya (Department of Bioinformatics, School of Bioengineering, SRM University)
  • Received : 2016.01.31
  • Accepted : 2016.03.25
  • Published : 2016.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Hepatitis B virus is the leading source of liver disorders and is a global health problem and needs advancements in its treatment against increasing problems. Recently five vanitaracin derivatives were isolated from the fungus Talaromyces species which have anti-Hepatitis B virus activity. Hence, in the present study, molecular docking was carried out with five vanitaracin derivatives isolated from Talaromyces species and three known inhibitors.The objective of this work is to study the interaction of newly isolated compounds and compare its interaction with known inhibitors. The docking results revealed that vanitaracin derivatives have good interactions and has better docking score with the Hepatitis B virus and suggest SER2, SER4 and ASP30 are important residues involved in interaction with the inhibitors. These result authenticates vanitaracin derivatives contributes to inhibitory activity of Hepatitis B virus to treat liver disorders.

Keywords

References

  1. T. J. Liang, "Hepatitis B: the virus and disease", Hepatology, Vol. 49, pp. S13-S21, 2009. https://doi.org/10.1002/hep.22881
  2. N. Gitilin, "HepatitisB: diagnosis, prevention and treatment", Clin. Chem., Vol. 43, pp. 1500-1506, 1997.
  3. M. Rizzetto and A. Ciancio, "Chronic HBV-related liver disease", Mol. Aspects Med., Vol. 29, pp. 72-84, 2008. https://doi.org/10.1016/j.mam.2007.09.013
  4. N. Liu, F. Zhao, H. Jia, D. Rai, P. Zhan, X. Jiang, and X. Liu, "Non-nucleoside anti-HBV agents: advances in structural optimization and mechanism of action investigations", Med. Chem. Commun., Vol. 6, pp. 521-535, 2015. https://doi.org/10.1039/C4MD00521J
  5. D. Lavanchy, "Hepatitis B virus epidemiology, disease burden, treatment, current and emerging prevention and control measures", J. Viral Hepatitis, Vol.11, pp. 97-107, 2004. https://doi.org/10.1046/j.1365-2893.2003.00487.x
  6. K. H. Kim, N. D. Kim, and B. L. Seong, "Discovery and development of anti-HBV agents and their resistance", Molecules, Vol. 15, pp. 5878-5908, 2010. https://doi.org/10.3390/molecules15095878
  7. Y. Li, L. Fu, H. Yeo, J. L. Zhu, C. K. Chou, Y. H. Kou, S. F. Yeh, E. Gullen, D. Austin, and Y. C. Cheng, "Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative", Antiviral Chemistry & Chemotherapy, Vol. 16, pp. 193-201, 2005. https://doi.org/10.1177/095632020501600305
  8. E. De Clercq, G. Ferir, S. Kaptein, and J. Neyts, "Antiviral treatment of chronic hepatitis B virus (HBV) infections", Viruses, Vol. 2, pp.1279-1305, 2010. https://doi.org/10.3390/v2061279
  9. H. Kwon and A. S. Lok, "Hepatitis B therapy", Nat. Rev. Gastro. Hepat., Vol. 8, pp. 275-284, 2011. https://doi.org/10.1038/nrgastro.2011.33
  10. T. M. Block, R. Gish, H. Guo, A. Mehta, A. Cuconati, W. T. London, and J. Guo, "Chronic hepatitis B: what should be the goal for new therapies?", Antivir. Res., Vol. 98, pp. 27-34, 2013. https://doi.org/10.1016/j.antiviral.2013.01.006
  11. B. Liu, X. Wen, C. Huang, and Y. Wei, "Unraveling the complexity of hepatitis B virus: From molecular understanding to therapeutic strategy in 50 years", Int. J. Biochem. Cell B., Vol. 45, pp. 1987-1996, 2013. https://doi.org/10.1016/j.biocel.2013.06.017
  12. K. Sato and M. Mori, "Current and novel therapies for Hepatitis B virus infection", Mini-Rev. Med. Chem., Vol. 10, pp. 20-31, 2010. https://doi.org/10.2174/138955710791112613
  13. F. Zoulim and S. Locarnini, "Management of treatment failure in chronic hepatitis B", J. Hepatol., Vol. 56, pp. S112-S122, 2012.
  14. A. S. Lok, "Combination Nucleos(t)ide Analogue as Initial Treatment for Chronic Hepatitis B: Have We Put This to Rest?", Hepatology, Vol. 58, pp. 483-485, 2013. https://doi.org/10.1002/hep.26337
  15. P. R. Daga, J. Duan, and R. J. Doerksen, "Computational model of hepatitis B virus DNA polymerase: Molecular dynamics and docking to understand resistant mutations", Protein Sci., Vol. 19, pp. 796-807, 2010. https://doi.org/10.1002/pro.359
  16. S. Locarnini, and W. S. Mason, "Cellular and virological mechanisms of HBV drug resistance", J. Hepatol., Vol. 44, pp. 422-431, 2006. https://doi.org/10.1016/j.jhep.2005.11.036
  17. F. Perveen, R. Qureshi, F. L. Ansari, S. Kalsoom, and S. Ahmed, "Investigations of drug-DNA interactions using molecular docking, cyclic voltammetry and UV-Vis spectroscopy", J. Mol. Struct., Vol. 1004, pp. 67-73, 2011. https://doi.org/10.1016/j.molstruc.2011.07.027
  18. B. Sathya, "Molecular docking study of naturally-derived neuraminidase inhibitors isolated from phellinus baumii", J. Chosun Natural Sci. Vol. 8, pp. 209-213, 2015. https://doi.org/10.13160/ricns.2015.8.3.209
  19. M. Thirumurthy, "A docking study of newly found natural neuraminidase inhibitor: Erystagallin A", J. Chosun Natural Sci., Vol. 4, pp. 273-277, 2011.
  20. C. G. Gadhe, "Comparative modeling of human P-gp NBD2 and docking and binding mode analysis of 8-geranyl chrysin as a P-gp modulator", J. Chosun Natural Sci., Vol. 5, pp. 18-21, 2012. https://doi.org/10.13160/ricns.2012.5.1.018
  21. SYBYL Software, Tripos Associates Inc, St. Louis, USA, 2006.
  22. The PyMOL Molecular Graphics System, Version 1.7.4 Schrodinger, LLC.
  23. H. Matsunaga, S. Kamisuki, M. Kaneko, Y. Yamaguchi, T. Takeuchi, K. Watashi, and F. Sugawara, "Isolation and structure of vanitaracin A, a novel anti-hepatitis B viruscompound from Talaromyces sp.", Bioorg. Med. Chem. Lett., Vol. 25, pp. 4325-4328, 2015. https://doi.org/10.1016/j.bmcl.2015.07.067
  24. A. N. Jain, "Scoring functions for protein-ligand docking", Curr. Protein Pept. sc., Vol. 7, pp. 407-420, 2006. https://doi.org/10.2174/138920306778559395
  25. A. N. Jain, "Scoring non-covalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities", J. Comput. Aid. Mol. Des., Vol. 10, pp. 427-440, 1996. https://doi.org/10.1007/BF00124474